Urapidil

DB12661InvestigationalSmall molecule

Urapidil is a combination adrenergic antagonist and serotonin agonist given orally for the treatment of essential hypertension and intravenously in hypertensive emergencies. Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

Chemical structure of Urapidil
Formula / weight
C20H29N5O3 · 387.484 g/mol (avg)

Resolves to

Compound
UNIIA78GF17HJSCAS34661-75-1ChEMBLCHEMBL279229ChEBI32278PubChem5639
Clinical / RWD
RxNorm39230ATCC02CA06
Structure
InChIKeyICMGLRUYEQNHPF-UHFFFAOYSA-NSMILESCOC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1
Targets
P08908HTR1A

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1,185Drug interactionsStructured to mechanism, not free text
Sign in
19Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5ContraindicationsEach with its own population and attribute set
Sign in
104Marketed productsAcross 5 countries and 15 labellers
Sign in
1ATC codeIncluding every combination product, plus 15 drug categories
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Urapidil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In